MSH2 and adenoma: Furthermore, only 16.7–36.4% of colorectal adenomas from pathogenic MSH6 variant carriers were shown to be MMR deficient, much lower than the 63–92% of adenomas from MLH1 or MSH2 variant carriers in the same studies [68,69].